Effects of simvastatin on circulating autoantibodies to oxidized LDL antigens: relation with immune stimulation markers

References

• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–1695
   PubMed Web of Science ®Google Scholar
• Fredrikson GN, Hedblad B, Berglund G, Alm R, Ares M, Cercek B, Chyu KY, Shah PK, Nilsson J. Identification of immune responses against aldehyde-modified peptide sequences in ApoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23: 872–878
   PubMed Web of Science ®Google Scholar
• Ogawa H, Soejima H, Takazoe K, Miyamoto S, Kajiwara I, Shimomura H, Sakamoto T, Yoshimura M, Kugiyama K, Kimura M, Yasue H. Increased autoantibodies against oxidized low-density lipoprotein in coronary circulation in patients with coronary spastic angina. Angiology 2001; 52: 167–174
   PubMedGoogle Scholar
• Fredrikson GN, Soderberg I, Lindholm M, Dimayuga P, Chyu KY, Shah PK, Nilsson J. Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003; 23: 879–884
   PubMed Web of Science ®Google Scholar
• Wu R, Lemne C, de Faire U, Frostegard J. Antibodies to lysophosphatidylcholine are decreased in borderline hypertension. Hypertension 2001; 37: 154–159
   PubMedGoogle Scholar
• Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H, Emoto M, Kawagishi T, Morii H. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000; 148: 171–177
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reeactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20–28
   PubMed Web of Science ®Google Scholar
• Brumeanu TD, Goldstein R, Casares S. Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clin immunol (Orlando) 2006; 119: 1–12
   PubMedGoogle Scholar
• Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, McInnes IB. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524–1530
   PubMed Web of Science ®Google Scholar
• Aprahamian T, Bonegio R, Rizzo J, Perlman H, Lefer DJ, Rifkin IR, Walsh K. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol 2006; 177: 3028–3034
   PubMed Web of Science ®Google Scholar
• Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004; 173: 7641–7646
   PubMedGoogle Scholar
• Inoue T, Takayanagi K, Hayashi T, Morooka S. Fluvastatin attenuates nitrate tolerance in patients with ischemic heart disease complicating hypercholesterolemia. Int J Cardiol 2003; 90: 181–188
   PubMed Web of Science ®Google Scholar
• Rodenburg J, Vissers MN, Wiegman A, Miller ER, Ridker PM, Witztum JL, Kastelein JJ, Tsimikas S. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol 2006; 47: 1803–1810
   PubMedGoogle Scholar
• Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharm 2006; 61: 262–274
   PubMed Web of Science ®Google Scholar
• Choi SH, Chae A, Miller E, Messig M, Ntanios F, DeMaria AN, Nissen SE, Witztum JL, Tsimikas S. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol 2008; 52: 24–32
   PubMed Web of Science ®Google Scholar
• Cherfan P, Tompa A, Wikby A, Lofgren S, Jonasson L. Effects of simvastatin on human T cells in vivo. Atherosclerosis 2007; 193: 186–192
   PubMed Web of Science ®Google Scholar
• Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990; 10: 325–335
   PubMedGoogle Scholar
• Goncalves I, Gronholdt ML, Soderberg I, Ares MP, Nordestgaard BG, Bentzon JF, Fredrikson GN, Nilsson J. Humoral immune response against defined oxidized low-density lipoprotein antigens reflects structure and disease activity of carotid plaques. Arterioscler Thromb Vasc Biol 2005; 25: 1250–1255
   PubMed Web of Science ®Google Scholar
• van Tits LJ, Smilde TJ, van Wissen S, de Graaf J, Kastelein JJ, Stalenhoef AF. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J Invest Med 2004; 52: 177–184
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004; 110: 1406–1412
   PubMedGoogle Scholar
• Brugaletta S, Biasucci LM, Pinnelli M, Biondi-Zoccai G, Di Giannuario G, Trotta G, Liuzzo G, Crea F. Novel anti-inflammatory effect of statins: reduction of CD4+CD28null T lymphocyte frequency in patients with unstable angina. Heart 2006; 92: 249–250
   PubMedGoogle Scholar
• Jonasson L, Tompa A, Wikby A. Expansion of peripheral CD8+T cells in patients with coronary artery disease: relation to cytomegalovirus infection. J Intern Med 2003; 254: 472–478
   PubMed Web of Science ®Google Scholar
• Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, Traverso P, Villaggio B, Ferrera A, Kunkl A, Rizzi M, Ferrera F, Balestra P, Ghio M, Contini P, Setti M, Olive D, Azzarone B, Carmignani G, Ravetti JL, Torre G, Indiveri F. CD8+ CD28 − T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007; 179: 4323–4334
   PubMed Web of Science ®Google Scholar
• Menager-Marcq I, Pomie C, Romagnoli P, van Meerwijk JP. CD8+CD28 − regulatory T lymphocytes prevent experimental inflammatory bowel disease in mice. Gastroenterology 2006; 131: 1775–1785
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen N, Chen G, You P. The protective effect of CD8+CD28 − T suppressor cells on the acute rejection responses in rat liver transplantation. Transplant Proc 2007; 39: 3396–3403
   PubMedGoogle Scholar
• Arai K, Yamamura S, Seki S, Hanyu T, Takahashi HE, Abo T. Increase of CD57+T cells in knee joints and adjacent bone marrow of rheumatoid arthritis (RA) patients: implication for an anti-inflammatory role. Clin Exp Immunol 1998; 111: 345–352
   PubMed Web of Science ®Google Scholar